<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354808</url>
  </required_header>
  <id_info>
    <org_study_id>ACCEL-LOADING</org_study_id>
    <nct_id>NCT01354808</nct_id>
  </id_info>
  <brief_title>ACCEL-LOADING-ACS Study</brief_title>
  <official_title>ACCELerated Inhibition of Platelet Aggregation, Inflammation and Ischemia-reperfusion Injury by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether adjunctive cilostazol loading/maintenance
      to standard treatment (aspirin, clopidogrel, and statin) is effective in reduction of major
      adverse cardiovascular events, platelet activation, inflammation and myonecrosis in patients
      with non-ST-elevation acute coronary syndrome (ACS)undergoing percutaneous coronary
      intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In ACS patients, platelet activation, inflammation, and ischemia-reperfusion injury can be
      closely associated with the risk of post-PCI myonecrosis and ischemic events occurrence. In
      the ACCEL-AMI (Adjunctive Cilostazol versus high maintenance-dose ClopidogrEL in patients
      with Acute Myocardial Infarction)study, adjunctive cilostazol increased platelet inhibition
      compared with double-dose clopidogrel. Meanwhile, statins can reduce the extent of
      myonecrosis via limiting inflammation and myocardial infarct size by activating
      phosphatidylinositol-3-kinase (PI3K), ecto-5'-nucleotidase, Akt/endothelial nitric oxide
      synthase (eNOS), and the downstream effectors inducible nitric oxide synthase (iNOS) and
      cyclooxygenase-2 (COX-2). Inhibition of PI3K, adenosine receptors, eNOS, iNOS, or COX-2
      abrogates the protective effects of statins. In animal study, the combination of low-dose
      statin with cilostazol synergistically limits infarct size. Multiple studies have shown that
      cilostazol can influence inflammation and RISK pathway using the similar pathway with statin.
      This study will be performed to evaluate the role of adjunctive cilostazol in platelet
      inhibition, inflammation, and myonecrosis compared with standard treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>1 month</time_frame>
    <description>Composite of cardiac death, MI and ischemia-driven target lesion revascularization (TLR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>P2Y12 reaction unit levels in the 2 arms</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE incidence according to P2Y12 reaction unit</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any post-procedural increase of markers of myocardial injury above ULN</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-procedural variations from baseline of hs-CRP levels in the 2 arms</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACUITY major/minor bleeding rate</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24hr post-procedural variations from baseline of inflammation markers (IL-6, TNF-alpha, cell adhesion molecules (VCAM, ICAM, E-selectin)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Platelet Aggregation Inhibitors</condition>
  <condition>Anti-inflammatory Agent</condition>
  <condition>Myocardial Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual Anti-Platelet Therapy (DAPT)</intervention_name>
    <description>Loading: aspirin 300mg + clopidogrel 600mg
Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month</description>
    <arm_group_label>DAPT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple Anti-Platelet Therapy (TAPT)</intervention_name>
    <description>Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg
Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month</description>
    <arm_group_label>TAPT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 years of age

          -  Non-ST-elevation ACS patients undergoing PCI within 48 hours after hospitalization

        Exclusion Criteria:

          -  ST segment elevation acute myocardial infarction

          -  NSTE ACS with high-risk features warranting emergency coronary angiography

          -  Oral anticoagulation therapy with warfarin

          -  Use of pre-procedural glycoprotein IIb/IIIa inhibitor

          -  Contraindication to antiplatelet therapy

          -  AST or ALT ≥ 3 times upper normal

          -  Left ventricular ejection fraction &lt; 30%

          -  WBC &lt; 3,000/mm3, platelet &lt; 100,000/mm3

          -  Creatinine ≥ 3 mg/dl

          -  stroke within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyounghoon Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gil hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae-Hyeong Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keun-Ho Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center of Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon Suh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soon Chun Hyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Yong Yoo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangneung Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gyeonsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <state>Gyeonsangnam-do</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007 Mar 27;49(12):1272-8.</citation>
    <PMID>17394957</PMID>
  </results_reference>
  <results_reference>
    <citation>Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, Kwak CH, Park SW. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv. 2010 Feb 1;3(1):17-26. doi: 10.1161/CIRCINTERVENTIONS.109.880179. Epub 2010 Jan 26.</citation>
    <PMID>20118150</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cilostazol</keyword>
  <keyword>Platelet</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Myonecrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Myocardial Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

